Anna Salmela1, Niels Rasmussen2, Jan Willem Cohen Tervaert3, David R W Jayne4, Agneta Ekstrand5. 1. Department of Internal Medicine, Vaasa Central Hospital, Vaasa, Finland. 2. Department of Biochemistry and Immunology, Statens Seruminstitut, Copenhagen, Denmark. 3. Department of Immunology, Maastricht University, Maastricht, The Netherlands. 4. Department of Medicine, University of Cambridge, Cambridge, UK. 5. Abdomen Center, Nephrology, Helsinki University Hospital, Helsinki, Finland.
Abstract
Objective: The aim of this study was to evaluate whether chronic nasal carriage of Staphylococcus aureus (SA) is related to relapses in patients with newly diagnosed ANCA-associated vasculitis (AAV). Methods:In two clinical trials (n = 200), for early systemic (n = 83) and generalized (n = 117) AAV, nasal swabs were obtained monthly and at the time of a relapse. Chronic nasal SA carriage (CNSAC) was defined as ⩾ 75% of cultures being SA positive, with non-carriers being SA negative in all cultures and remaining patients being intermittent carriers. Fifty-five of 200 (27.5%) patients received prophylactic trimethoprim/sulfamethoxazole (T/S) against Pneumocystis jirovecii . Results: Of the total AAV patients, 24/200 (12%) were chronic, 102/200 (51%) intermittent and 74/200 (37%) non-carriers. Of 65 relapsing patients, 10/24 (41.7%) were chronic, 32/102 (31.4%) intermittent and 23/74 (31.1%) non-carriers (P = 0.59). For all AAV patients, CNSAC was not associated with an increased relapse risk [odds ratio (OR) = 1.57, 95% CI: 0.66, 3.76; P = 0.31]. However, 23/24 chronic carriers had granulomatosis with polyangiitis (GPA). In the 73 patients with generalized GPA (hazard ratio = 4.10, 95% CI: 1.37, 12.25; P = 0.01) and the 78 patients with early systemic GPA during immunosuppression (hazard ratio = 2.73, 95% CI: 0.95, 7.87; P = 0.06), relapse rates were higher for chronic SA carriers. Prophylactic T/S was not associated with a reduced relapse risk (OR = 0.71, 95% CI: 0.36, 1.41; P = 0.33). Nevertheless, prophylactic T/S reduced CNSAC (OR = 0.19, 95% CI: 0.04, 0.91; P = 0.04). Conclusion: The frequency of CNSAC in newly diagnosed GPA paralleled that in the general population. This subset of GPA patients (23/151, 15.2%) has a high relapse rate despite immunosuppression and prophylactic T/S treatment, requiring further investigations on pathogenesis and therapy.
RCT Entities:
Objective: The aim of this study was to evaluate whether chronic nasal carriage of Staphylococcus aureus (SA) is related to relapses in patients with newly diagnosed ANCA-associated vasculitis (AAV). Methods: In two clinical trials (n = 200), for early systemic (n = 83) and generalized (n = 117) AAV, nasal swabs were obtained monthly and at the time of a relapse. Chronic nasal SA carriage (CNSAC) was defined as ⩾ 75% of cultures being SA positive, with non-carriers being SA negative in all cultures and remaining patients being intermittent carriers. Fifty-five of 200 (27.5%) patients received prophylactic trimethoprim/sulfamethoxazole (T/S) against Pneumocystis jirovecii . Results: Of the total AAV patients, 24/200 (12%) were chronic, 102/200 (51%) intermittent and 74/200 (37%) non-carriers. Of 65 relapsing patients, 10/24 (41.7%) were chronic, 32/102 (31.4%) intermittent and 23/74 (31.1%) non-carriers (P = 0.59). For all AAV patients, CNSAC was not associated with an increased relapse risk [odds ratio (OR) = 1.57, 95% CI: 0.66, 3.76; P = 0.31]. However, 23/24 chronic carriers had granulomatosis with polyangiitis (GPA). In the 73 patients with generalized GPA (hazard ratio = 4.10, 95% CI: 1.37, 12.25; P = 0.01) and the 78 patients with early systemic GPA during immunosuppression (hazard ratio = 2.73, 95% CI: 0.95, 7.87; P = 0.06), relapse rates were higher for chronic SA carriers. Prophylactic T/S was not associated with a reduced relapse risk (OR = 0.71, 95% CI: 0.36, 1.41; P = 0.33). Nevertheless, prophylactic T/S reduced CNSAC (OR = 0.19, 95% CI: 0.04, 0.91; P = 0.04). Conclusion: The frequency of CNSAC in newly diagnosed GPA paralleled that in the general population. This subset of GPA patients (23/151, 15.2%) has a high relapse rate despite immunosuppression and prophylactic T/S treatment, requiring further investigations on pathogenesis and therapy.
Authors: Marcia A Friedman; Dongseok Choi; Stephen R Planck; James T Rosenbaum; Cailin H Sibley Journal: J Rheumatol Date: 2019-01-15 Impact factor: 4.666
Authors: Corinna Glasner; Marcus C de Goffau; Mirjan M van Timmeren; Mirja L Schulze; Benita Jansen; Mehri Tavakol; Willem J B van Wamel; Coen A Stegeman; Cees G M Kallenberg; Jan P Arends; John W Rossen; Peter Heeringa; Jan Maarten van Dijl Journal: Sci Rep Date: 2017-09-22 Impact factor: 4.379
Authors: Joshua D Ooi; Jhih-Hang Jiang; Peter J Eggenhuizen; Ling L Chua; Mirjan van Timmeren; Khai L Loh; Kim M O'Sullivan; Poh Y Gan; Yong Zhong; Kirill Tsyganov; Lani R Shochet; Jessica Ryan; Coen A Stegeman; Lars Fugger; Hugh H Reid; Jamie Rossjohn; Peter Heeringa; Stephen R Holdsworth; Anton Y Peleg; A Richard Kitching Journal: Nat Commun Date: 2019-07-29 Impact factor: 14.919
Authors: Rennie L Rhee; Jiarui Lu; Kyle Bittinger; Jung-Jin Lee; Lisa M Mattei; Antoine G Sreih; Sherry Chou; Jonathan J Miner; Noam A Cohen; Brendan J Kelly; Hongzhe Lee; Peter C Grayson; Ronald G Collman; Peter A Merkel Journal: Arthritis Rheumatol Date: 2021-07-31 Impact factor: 15.483